# DESCRIPTION

## STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

- acknowledge government support

## BACKGROUND

- motivate breast cancer research

## SUMMARY

- introduce method for identifying breast cancer patients at risk
- introduce method for detecting exhausted CD8+ T cells
- introduce method for treating breast cancer
- introduce method for identifying breast cancer patients with good prognosis
- introduce method for detecting CD26+CD4+ T cells

## DETAILED DESCRIPTION

### Definitions

- define technical terms
- provide dictionary references
- define T cells
- define CD4+ T cells
- define CD8+ T cells
- define exhausted CD8+ T cells
- define CD26
- define CD26+CD8+ T cells
- define PD-1+
- define remission
- define relapse
- define relapse-free survival
- define good prognosis
- define biological sample
- define peripheral blood
- define peripheral blood mononuclear cell
- define gene expression
- define pathway
- define control
- define breast cancer diagnosis method
- identify exhausted CD8+ T cells
- detect CD8+ T cell expression levels
- administer non-chemotherapeutic therapy
- treat breast cancer with non-chemotherapeutic therapy
- identify breast cancer patient for treatment
- predict increased risk of relapse or reduced survival
- detect gene expression levels from Table 1
- identify patient for chemotherapeutic therapy
- treat breast cancer with chemotherapeutic therapy
- monitor breast cancer progression
- determine treatment efficacy
- identify patient with increased risk of relapse or reduced survival
- administer chemotherapeutic therapy
- select patient for treatment with chemotherapeutic therapy
- determine breast cancer risk score
- apply Oncotype Dx test or equivalent
- resolve intermediate Breast Recurrence Score
- identify exhausted CD8+ T cells in intermediate risk score
- detect elevated gene expression levels in intermediate risk score
- administer chemotherapeutic therapy in intermediate risk score
- identify patient with increased risk of relapse or reduced survival in intermediate risk score
- select patient for treatment with chemotherapeutic therapy in intermediate risk score
- determine treatment efficacy in intermediate risk score
- monitor breast cancer progression in intermediate risk score
- define breast cancer risk scores
- identify intermediate breast cancer risk score
- identify low breast cancer risk score
- specify breast cancer types
- specify patient demographics
- describe biological samples
- introduce CD26+CD4+ T cells detection
- identify good prognosis
- identify increased risk of relapse or reduced survival
- describe non-chemotherapeutic therapy
- describe chemotherapeutic therapy
- detect increased level of CD26+CD4+ T cells
- treat breast cancer with chemotherapeutic therapy
- identify patient with increased risk of relapse or reduced survival
- select patient for chemotherapeutic therapy
- specify breast cancer subtypes
- specify patient demographics
- define breast cancer patient identification methods
- describe CD26+CD4+ T cells detection
- outline non-chemotherapeutic therapy administration
- specify breast cancer types and patient demographics
- describe gene expression level detection
- outline increased expression level of genes from Table 2
- outline decreased expression level of genes from Table 2
- describe unequally weighted average of gene expression levels
- specify genes from Table 2
- describe predicting increased risk of relapse or reduced survival
- outline identifying breast cancer patients for treatment
- describe monitoring breast cancer progression or treatment efficacy
- specify biological sample types
- describe treating breast cancer in patients
- outline administering non-chemotherapeutic therapy
- outline administering chemotherapeutic therapy
- specify breast cancer subtypes and patient demographics
- describe detecting gene expression levels in biological samples
- outline identifying breast cancer patients for treatment
- describe administering therapy based on gene expression levels
- specify biological sample types
- describe treating breast cancer in patients
- define breast cancer patient identification method
- describe method embodiments
- specify breast cancer types
- specify patient types
- describe biological sample types
- describe gene expression level detection
- describe chemotherapeutic therapy administration
- describe non-chemotherapeutic therapy administration
- specify hormone therapy
- describe increased gene expression level detection
- describe multiple gene expression level detection
- describe weighted average calculation
- describe exhausted CD8+ T cells detection
- describe CD26+CD4+ T cells detection
- describe patient risk identification
- describe patient treatment selection
- describe breast cancer treatment methods
- describe chemotherapeutic therapy methods
- describe non-chemotherapeutic therapy methods
- describe hormone therapy methods
- describe patient prognosis identification
- define methods of treating breast cancer
- specify patient and breast cancer types
- detect exhausted CD8+ T cells and CD26+CD4+ T cells
- administer chemotherapeutic therapy
- detect gene expression levels from Table 1 and Table 2
- identify gene expression levels relative to standard control
- administer therapy based on gene expression levels
- predict risk of relapse or reduced survival
- specify number of genes from Table 1 and Table 2
- calculate unequally weighted averages of gene expression levels
- describe detection methods for gene expression levels
- define RNA detection methods
- define protein detection methods
- calculate gene expression levels
- calculate protein expression levels
- define chemotherapeutic therapy
- describe chemotherapeutic agents
- define non-chemotherapeutic therapy
- describe hormone therapy
- describe immunotherapy and targeted therapy
- describe radiation therapy
- define effective amount
- define reduction
- describe therapeutically effective amount
- describe dosage determination
- describe administering
- introduce kits
- describe kit components
- describe RNA or protein microarrays
- describe assay systems
- describe means for detecting
- describe detectable tags or labels
- describe immobilization on a substrate
- describe kit contents and instructions
- define detection agent
- define detectable label
- define detectable complex
- define probe
- define hybridization complex
- define complementary
- define substantially complementary
- describe hybridization assays
- describe nucleic acid hybridization conditions
- define nucleic acid
- define DNA and RNA
- define amplifying
- define primer
- define identical or percent identity
- define solid support

### EXAMPLES

- introduce CD8+ tumor infiltrating lymphocytes (TTLs) in breast cancer
- associate TTLs with survival in triple negative breast cancer (TNBC) and estrogen receptor-positive (ER+) breast cancer
- identify subsets of breast cancer tumors infiltrated by CD8+ T cells with characteristic features of exhausted T cells (TEX)
- describe tumor microenvironment marked by amplified interferon-γ signaling related pathways and higher PD-L1 expression
- associate higher levels of CD8+ TEX TILs with decreased overall survival in ER+BC patients
- identify high tumor expression of a CD8+ TEX signature score in identifying high-risk premenopausal ER+BC patients
- examine BC patient peripheral blood mononuclear cells (PBMCs), tumor negative tumor draining lymph nodes (T− LNs), tumor positive tumor draining
- analyze CD8+ T cells expressing T cell exhaustion markers PD-1 and CD39
- identify PD-1+ CD39+ CD8+ TILs as functionally exhausted compared to other CD8+ TTLs
- examine expression of proteins CD127 (IL-7Rα) and KLRG1 to assess PD-1+ CD39+ CD8+
- illustrate PD-1+ CD39+ CD8+ TILs found in BC tumors as highly activated cells with both exhausted and tissue residency characteristics
- employ single cell RNA sequencing of patient CD8+ T cells from 10 different BC patients
- identify four major clusters with discrete gene expression patterns
- annotate the four CD8+ T cell clusters as exhausted T cells, resident effector memory T cells, effector memory T cells, and central memory
- analyze gene expression differences between clusters
- generate a TEX gene signature composed of genes significantly elevated in TEX relative to other CD8+ T cell populations
- compare TEX gene expression signature to TEX gene signatures produced by other groups
- associate CD8+ TEX with IFNγ signature rich and immunologically distinct tumors
- analyze immune composition between TEXhi and TEXlo tumors
- denote prognostic outcome in breast cancer patients
- introduce TEXhi ER+ tumors
- analyze survival characteristics
- examine TEX signature in Oncotype DX patients
- discuss TEX signature in premenopausal patients
- discuss TEX signature in postmenopausal patients
- analyze multivariate model
- discuss TEX signature in OncDXint patients
- discuss TEX signature in premenopausal OncDXint patients
- discuss TEX signature in postmenopausal OncDXint patients
- discuss CD8+ TEX in BC patients
- discuss IFNγ rich TME and reduced survival
- discuss TEX signature and tumor mutation burden
- discuss TEX signature and immune-cancer interaction
- discuss TEX signature and standard of care therapy
- discuss TEX signature and JAK-STAT signaling
- discuss TEX signature and estrogen receptor signaling
- discuss TEX signature and therapeutic strategy
- describe methods
- introduce public genomic data analysis
- download and organize METABRIC data
- calculate TEX signature scores
- perform survival comparison and Kaplan Meier curves
- implement Cox Proportional-Hazards model
- investigate association between TEX signature scores and molecular features
- perform differential expression analysis for TEXhi and TEXlo groups
- implement gene set enrichment analysis
- deconvolute METABRIC expression data using CIBERSORTx
- perform differential expression analysis between TEX high and TEX low cohorts
- calculate in-house Oncotype Dx scores
- perform survival comparison and analysis for CD8A expression
- describe additional statistics and study approval
- describe 25-gene signature of exhausted CD8+ T cells
- describe TEX and CD26+CD4+ signatures
- describe predictive accuracy of combined TEX:CD4+CD26+ signature
- describe human sample collection and processing
- describe sample processing and preparation
- describe flow cytometry analysis
- describe single-cell RNA sequencing and analysis
- describe public genomic data analysis
- describe multiplex immunofluorescence analysis
- describe additional statistical analysis
- describe study approval and data availability
- describe references for example 1
- describe references for example 2
- provide general statement on modifications and changes

